Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.39 |
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | HTR2B | P41595 | 7/20 | 0.39 |
| ▸ | TACR1 | P25103 | 9/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437077 | 0.78 | ALDH1A1 (0.43) | TACR1 | |
| SCHEMBL1769797 | 0.75 | TACR1 (0.43) | HTR2CHTR2AHTR2BTACR1 | |
| SCHEMBL5188507 | 0.75 | MAPT (0.38) | TACR1 | |
| SCHEMBL31257816 | 0.74 | ALDH1A1 (0.42) | HTR2CHTR2AHTR2B | |
| SCHEMBL30165832 | 0.74 | ALDH1A1 (0.50) | — | |
| SCHEMBL28052467 | 0.73 | TACR1 (0.40) | HTR2CHTR2AHTR2BTACR1 | |
| SCHEMBL30502301 | 0.72 | HTR2C (0.44) | HTR2CHTR2AHTR2BTACR1 | |
| SCHEMBL30968426 | 0.72 | TACR1 (0.33) | HTR2CHTR2AHTR2BTACR1 | |
| SCHEMBL31437059 | 0.72 | PARP1 (0.38) | TACR1 | |
| SCHEMBL13647340 | 0.72 | TACR1 (0.59) | HTR2CHTR2AHTR2BTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | HTR2C 4733/4885HTR2A 4389/4885HTR2B 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.